ViewPoints Interview: Arrowhead’ Dr. Christopher Anzalone Shares Insights on the Data of ARO-AAT Presented at EASL 2021
In an interview with PharmaShots, Dr. Christopher Anzalone, President and CEO at Arrowhead shared his views on the interim 48-week data from the P-II AROAAT2002 study evaluates the safety and PD effects of ARO-AAT for the treatment of liver disease due to AATD Shots: The P-II AROAAT2002 study evaluated the safety & PD effects of […]